Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Tech companies, facing legal risks and a new political climate, are scaling back, cutting or rethinking efforts focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback